key: cord-0078826-i2xu8uj3 authors: Hummel, Aurélie; Oniszczuk, Julie; Kervella, Delphine; Charbit, Marina; Guerrot, Dominique; Testa, Angelo; Philipponnet, Carole; Chauvet, Cécile; Guincestre, Thomas; Brochard, Karine; Benezech, Ariane; Figueres, Lucile; Belenfant, Xavier; Guarnieri, Andrea; Demoulin, Nathalie; Benetti, Elisa; Miglinas, Marius; Dessaix, Kathleen; Morelle, Johann; Angeletti, Andrea; Sellier-Leclerc, Anne-Laure; Ranchin, Bruno; Goussard, Guillaume; Hudier, Laurent; Bacchetta, Justine; Servais, Aude; Audard, Vincent title: Idiopathic nephrotic syndrome relapse following SARS-CoV-2 vaccination: a series of 25 cases date: 2022-05-06 journal: Clin Kidney J DOI: 10.1093/ckj/sfac134 sha: 08c50d0a1a4601acf21e02599c45e253d0169101 doc_id: 78826 cord_uid: i2xu8uj3 BACKGROUND: Several cases of idiopathic nephrotic syndrome (INS) relapse following the administration of COVID-19 vaccines have recently been reported, raising questions about the potential relationship between the immune response to SARS-CoV-2 vaccination and INS pathogenesis. METHODS: We performed a retrospective multicenter survey describing the clinical and biological characteristics of patients presenting a relapse of INS after COVID-19 vaccination, with an assessment of outcome under treatment. RESULTS: We identified 25 patients (16 men/9 women) presenting a relapse within one month of a COVID-19 vaccine injection. Glomerular disease was of childhood onset in half the patients and most patients (21/25) had received at least one immunosuppressive drug in addition to steroids for frequently relapsing or steroid-dependent NS. All patients were in a stable condition at the time of injection and 11 had no specific treatment. In 5 patients, the last relapse was reported more than five years before vaccine injection. The Pfizer-bioNTech vaccine was used in 80% of the patients. In 18 cases, INS relapse occurred after the first injection, a mean of 17.5 days after vaccination. A second injection was nevertheless administered in 14 of these patients. Five relapses occurred after administration of the second dose, and two relapses after the administration of third dose. All but one of the patients received steroids as first-line treatment, with an additional immunosuppressive agent in 9 cases. During follow-up, complete remission was achieved in 21 patients, within one month in 17 cases. Only one patient had not achieved at least partial remission after three months of follow-up. CONCLUSIONS: This case series suggests that, in rare patients, COVID-19 vaccination may trigger INS relapse that is generally easy to control. These findings should encourage physicians to persuade their patients to complete the anti-COVID 19 vaccination schedule. The molecular mechanisms underlying the pathophysiological processes of idiopathic nephrotic syndrome (INS) remain poorly understood, but this glomerular disease that includes two principal pathological entities: minimal change disease (MCD) and primary focal and segmental glomerulosclerosis (FSGS), is currently considered to be an immune-mediated disease [1] [2] [3] [4] . Indeed, relapses of INS may be triggered by immunological stimuli, such as viral infections (particularly those of the upper airways), immunization or allergens, supporting the hypothesis of a primary immune system disorder leading to changes in glomerular capillary permeability and disorganization of the podocyte cytoskeleton [1] [2] [3] [4] . Vaccination has long been considered a trigger of INS relapse, even though very few prospective data are available. A recent study in children with steroid-dependent nephrotic syndrome (SDNS) found no close relationship between vaccine administration and an increase in the risk of relapse [5] . INS patients are well known to be at high risk of episodes of infection, due to the use of immunosuppressive agents and alterations to both humoral and cell-mediated immunity during active phases of the disease. Thus, in INS patients, the benefitrisk ratio is clearly in favor of prophylactic vaccination provided that the contraindication of live vaccines is respected in cases of ongoing immunosupression [6] . In the context of the massive COVID-19 vaccination campaign worldwide, some cases of new-onset MCD [7] [8] [9] [10] [11] [12] [13] [14] or of MCD relapse [14] [15] [16] [17] [18] [19] [20] have been reported, suggesting a potential relationship between the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and MCD pathogenesis [21] . By contrast to the published cases of MCD, newonset or relapses of primary FSGS following COVID-19 vaccination seem to be an exceptional finding [22] . Two of the patients in this series were reported in previous publications, but detailed information was supplied by their physicians via the survey [15, 16] . Demographic, clinical, biological and histological data obtained at the initial diagnosis of idiopathic nephrotic syndrome and at the time of relapse after SARS-CoV-2 vaccine administration were assessed for each patient. Nephrotic syndrome was defined as a urine protein-creatinine ratio [uPCR] exceeding 3 g/g and a serum albumin concentration below 30 g/L. MCD was diagnosed on the basis of an absence of visible alterations on light microscopy examination, and an absence of immunoglobulin and/or complement deposits in immunofluorescence studies [3] . FSGS diagnosis was based on the presence of segmentally collapsed glomerular capillaries with areas of glomerular scarring associated with the focal and segmental granular deposition of IgM and/or C3 within the areas of segmental glomerular sclerosis [4] . Complete remission of nephrotic syndrome was defined as the normalization of We retrospectively identified 25 patients (16 men and 9 women) with a mean age of 25. The mean age of our patients at the time of relapse after vaccination was 39.7 years (range: 15-83 years) ( Table 2) . The time from last relapse (before vaccination) and the relapse after vaccination was known for 21 patients (mean: 56 months, range: 2 to 468 months). Ten of the patients had a relapse on the last 12 months. For 4 patients, the last relapse was diagnosed between one and three years before the relapse after vaccination, and seven patients had experienced no relapse in the previous three years. For one 40-year-old patient (patient 12), the only episode of the disease had occurred 39 years previously, at the age of one year. Biological data (uPCR and/or albumin level) during the year preceding vaccination were available for 20 patients ( Table 1) : uPCR was below 0.5 g/g in all but two patients: patient 13, for whom uPCR was 1.7 g/g, but albumin levels were in the normal range (42 g/l) before vaccination, decreasing significantly to 16 g/l during relapse, and patient 22, with uPCR at 1.2 g/g, increasing to 3.3 g/g, whereas albumin level decreased to 23 g/l after vaccination. At the time of the relapse, 11 patients were not receiving any specific treatment for INS. By contrast, steroid therapy was ongoing, with or without immunosuppressive agents, in 14 cases, to maintain complete remission of INS (5 patients received steroids alone, 4 received mycofenolate mofetil, two received rituximab and three received steroids plus another immunosuppressive treatment). All patients received their first injection of anti-SARS-COV2 vaccine between January and September 2021 ( Table 2) patients with a broad spectrum of immune-mediated glomerular diseases (including 7 MCD but also 10 IgA nephropathy, 6 crescentic glomerulonephritis and 3 membranous nephropathy) [26] We cannot rule out the possibility of these relapses or new onsets of MCD being related to vaccine administration, but these events seem to be a very rare finding [21] . system variants and steroid-sensitive MCD has also been suggested [1] . Interestingly, Caso et al. showed that genetic predispositions could influence the response to COVID-19 vaccines and their adverse effects [28] . Molecular mimicry, involving a cross-reaction with a host protein sequence, may also trigger autoimmune responses following COVID-19 vaccination [29] . As observed in seven previously published case reports (after exclusion of two cases previously reported and added to our case series [15, 16] ) summarized in Table 3 19 vaccination schedule. Given the severity of COVID-19 in immunocompromised patients [30] , even if the production of vaccine-specific antibodies is impaired in patients on immunosuppressive agents [31] [32] Immunology of idiopathic nephrotic syndrome Immunopathogenesis of idiopathic nephrotic syndrome with relapse Minimal change disease Focal segmental glomerulosclerosis Vaccines and disease relapses in children with nephrotic syndrome Vaccine recommendations for children with idiopathic nephrotic syndrome Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine An additional case of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine Post-vaccinal minimal change disease Nephrotic syndrome following ChAdOx1 nCoV-19 vaccine against SARScoV-2 Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report Report of three cases of minimal change disease following the second dose of mRNA SARS-CoV-2 COVID-19 vaccine Minimal change disease following vaccination for SARS-CoV-2 Minimal change disease relapse following SARS-CoV-2 mRNA vaccine Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine Relapse of minimal change disease after inactivated SARS-CoV-2 vaccination: case report Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? COVID-19 vaccination and glomerulonephritis Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury Tailoring mRNA vaccine to balance innate/adaptive immune response Distinct glomerular disease association after vaccination with BNT162b2 and mRNA-1273: A Vigibase analysis Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses Could SARS-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants Evaluation of immune and vaccine competence in steroid-sensitive nephrotic syndrome pediatric patients Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients The authors received no specific financial support for this study. Dr Audard received consulting fees from Addmedica, Travere, Alnylam and Astrazeneca outside of the submitted work. None of the other authors has any conflict of interest to declare.